NBP
NovaBridge Biosciences
NASDAQ · Healthcare · Biotechnology · US
$1.80
+0.00%0
Insider buys (3m)
3
Insider sells (3m)
-$12.2K
Net value (3m)
+8.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Xu Cong Claire · officer: EVP, Clinical Development | Sale | 3,282 | $0.79 |
| Sep 1, 2026 | Xu Cong Claire · officer: EVP, Clinical Development | M-Exempt | 9,382 | $0.00 |
| Sep 1, 2026 | Xu Cong Claire · officer: EVP, Clinical Development | M-Exempt | 4,079 | $0.00 |
| Aug 25, 2026 | Lenz Robert A. · director | M-Exempt | 7,486 | $0.00 |
| Aug 25, 2026 | Lenz Robert A. · director | M-Exempt | 17,218 | $0.00 |
| Jul 10, 2026 | Hagler Mark Arnold · officer: Chief Commercial Officer | A-Award | 949,050 | $1.93 |
| Jul 10, 2026 | Lin Liwei Lorraine · officer: General Counsel | A-Award | 254,780 | $1.93 |
| Jul 8, 2026 | Gupta Srishti · director, officer: Chief Executive Officer | A-Award | 3,000,000 | $2.01 |
| Jul 7, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | M-Exempt | 5,405 | $0.00 |
| Jul 7, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | M-Exempt | 12,432 | $0.00 |
| Jul 7, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | Sale | 4,485 | $0.89 |
| Jun 30, 2026 | Fu Wei · director | A-Award | 1,010,100 | $0.00 |
| Jun 30, 2026 | Fu Wei · director | A-Award | 725,140 | $2.45 |
| Jun 30, 2026 | Fu Wei · director | A-Award | 1,087,720 | $2.45 |
| Jun 24, 2026 | Cao Sean Wuxiong · director, officer: Chief Bus. Development Officer | A-Award | 181,290 | $1.53 |
| Jun 24, 2026 | Cao Sean Wuxiong · director, officer: Chief Bus. Development Officer | A-Award | 181,280 | $0.00 |
| Jun 22, 2026 | Dennis Phillip Andrew · officer: Chief Medical Officer | M-Exempt | 23,695 | $0.00 |
| Jun 22, 2026 | Dennis Phillip Andrew · officer: Chief Medical Officer | M-Exempt | 10,302 | $0.00 |
| Jun 22, 2026 | Dennis Phillip Andrew · officer: Chief Medical Officer | Sale | 8,494 | $0.66 |
| Jun 2, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | M-Exempt | 9,382 | $0.00 |
| Jun 2, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | Sale | 3,494 | $3.94 |
| Jun 2, 2026 | Xu Cong Claire · officer: SVP, Clinical Development | M-Exempt | 4,079 | $0.00 |
| May 18, 2026 | Cao Sean Wuxiong · director, officer: See Remarks | Sale | 21,399 | $1.99 |
| Apr 28, 2026 | Hagler Mark Arnold · officer: See Remarks | Purchase | 230,000 | $2.51 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 1, 2026